Search Page

1

Cite

Share

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB. Gerding DN, et al. Among authors: hanson me. Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171. Clin Infect Dis. 2018. PMID: 29538686 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

Development of Pandemic Vaccines: ERVEBO Case Study.

Wolf J, Jannat R, Dubey S, Troth S, Onorato MT, Coller BA, Hanson ME, Simon JK. Wolf J, et al. Among authors: hanson me. Vaccines (Basel). 2021 Feb 25;9(3):190. doi: 10.3390/vaccines9030190. Vaccines (Basel). 2021. PMID: 33668698 Free PMC article. Review.

Cite

Share

3

Cite

Share

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS. Steinberg H, et al. Among authors: hanson me. Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330. Epub 2013 May 29. Vasc Health Risk Manag. 2013. PMID: 23761972 Free PMC article. Review.

Cite

Share

4

Cite

Share

Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.

Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB. Golan Y, et al. Among authors: hanson me. Open Forum Infect Dis. 2021 Jan 20;8(1):ofaa629. doi: 10.1093/ofid/ofaa629. eCollection 2021 Jan. Open Forum Infect Dis. 2021. PMID: 33511241 Free PMC article.

Cite

Share

5

Cite

Share

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Morrone D, et al. Among authors: hanson me. Atherosclerosis. 2012 Aug;223(2):251-61. doi: 10.1016/j.atherosclerosis.2012.02.016. Epub 2012 Feb 16. Atherosclerosis. 2012. PMID: 22410123 Review.

Cite

Share

6

Cite

Share

Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.

Bouza E, Cornely OA, Ramos-Martinez A, Plesniak R, Ellison MC, Hanson ME, Dorr MB. Bouza E, et al. Among authors: hanson me. Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):1933-1939. doi: 10.1007/s10096-020-03935-3. Epub 2020 Jun 6. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32504314 Free PMC article.

Cite

Share

7

Cite

Share

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.

Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB. Golan Y, et al. Among authors: hanson me. Open Forum Infect Dis. 2020 Jun 26;7(7):ofaa248. doi: 10.1093/ofid/ofaa248. eCollection 2020 Jul. Open Forum Infect Dis. 2020. PMID: 32685606 Free PMC article.

Cite

Share

8

Cite

Share

Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.

Grais RF, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BA, Welebob C, Hanson ME, Simon JK. Grais RF, et al. Among authors: hanson me. Lancet Microbe. 2021 Feb;2(2):e70-e78. doi: 10.1016/S2666-5247(20)30198-1. Epub 2021 Feb 2. Lancet Microbe. 2021. PMID: 35544244 Free article.

Cite

Share

9

Cite

Share

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr MB, Marcella S. Prabhu VS, et al. Among authors: hanson me. Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523. Clin Infect Dis. 2017. PMID: 30060024 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.

Kosoglou T, Kumar B, Statkevich P, Schiller JE, Kantesaria B, Hanson ME, Sisk CM, Cutler DL. Kosoglou T, et al. Among authors: hanson me. Clin Pharmacol Drug Dev. 2015 Jan;4(1):56-62. doi: 10.1002/cpdd.133. Epub 2014 Sep 28. Clin Pharmacol Drug Dev. 2015. PMID: 27128003 Clinical Trial.

Cite

Share